Correction: Perampanel as first add-on antiseizure medication: Italian consensus clinical practice statements
Main Authors: | Paolo Bonanni, Antonio Gambardella, Paolo Tinuper, Benedetto Acone, Emilio Perucca, Giangennaro Coppola |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-05-01
|
Series: | BMC Neurology |
Online Access: | https://doi.org/10.1186/s12883-022-02701-6 |
Similar Items
-
Effectiveness of perampanel as the only add‐on: Retrospective, multicenter, observational real‐life study on epilepsy patients
by: Sara Gasparini, et al.
Published: (2022-12-01) -
The 50th anniversary of the Italian League Against Epilepsy (Lega Italiana Contro l’Epilessia)
by: Laura Tassi, et al.
Published: (2022-01-01) -
The Effect of Plasma Protein Binding on the Therapeutic Monitoring of Antiseizure Medications
by: Bruno Charlier, et al.
Published: (2021-08-01) -
Perampanel Confirms to Be Effective and Well-Tolerated as an Add-On Treatment in Patients With Brain Tumor-Related Epilepsy (PERADET Study)
by: Antonietta Coppola, et al.
Published: (2020-06-01) -
Efficacy and safety of add‐on antiseizure medications for focal epilepsy: A network meta‐analysis
by: Hesheng Zhang, et al.
Published: (2024-08-01)